← Leaderboards
Catherine Sibyl Diefenbach
New York University School Of Medicine
$4,196,638
Attributed
$5,398,982
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,398,982 · 4
By mechanism
R01$5,175,266 · 2
R03$169,500 · 1
P30$54,216 · 1
Top collaborators
- Neville Sanjana3 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Morton Lippmann$1,151,998
- Jose U. Scher$5,083,770
- Roy E. Shore$4,559,031
- James Speyer$342,286
- Richard Bernard Hayes$7,406,813
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseLymphomaMalignant NeoplasmsS LymphomaSamplingCytokineLarge Cell Diffuse Non-Hodgkin&AposBiologicalT-LymphocyteCellsMyeloid CellsProspectiveBehaviorPlayClinical TrialsInnovationImmune SystemImmunityImmuneImmune ActivationRelapseRefractoryClinical EfficacyFda Approved
Grant awards (10)
LTBR CARs as next-generation therapies for R/R lymphoma$810,022
R01 · FY2025 · CA
A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity$700,561
R01 · FY2025 · CA · contact PI
LTBR CARs as next-generation therapies for R/R lymphoma$762,975
R01 · FY2024 · CA
A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity$665,532
R01 · FY2024 · CA · contact PI
LTBR CARs as next-generation therapies for R/R lymphoma$831,692
R01 · FY2023 · CA
A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity$686,548
R01 · FY2023 · CA · contact PI
Protocol Review and Monitoring System$54,216
P30 · FY2023 · CA · contact PI
A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity$717,936
R01 · FY2022 · CA · contact PI
A Novel Multimodality Immune Based Platform in Advanced Mycosis Fungoides$84,750
R03 · FY2015 · CA · contact PI
A Novel Multimodality Immune Based Platform in Advanced Mycosis Fungoides$84,750
R03 · FY2014 · CA · contact PI